Neurocognitive effects of proanthocyanidin in Alzheimer's disease: a systematic review of preclinical evidence – PubMed Black Hawk Supplements

Abstract

Cognitive disorders and dementia largely influence individual independence and orientation. Based on the Alzheimer’s Disease International (ADI) estimation, approximately 75% of individuals with dementia are undiagnosed. In fact, in some low- and middle-income countries, the percentage is as high as 90%. In this systematic review, which is based on PRISMA guidelines, we aim to identify the mechanism of action of proanthocyanidin. Finding a natural product alternative as a potential nootropic can help increase the number of armamentariums against dementia and other cognitive impairments. In this preclinical research, we determined the effect of proanthocyanidins on Alzheimer’s disease (AD) by searching electronic bibliographic databases like Scopus, Proquest, ScienceDirect, PubMed, and Google. There was no imposed time limit. However, the search was limited to only English articles. The review protocol is registered on PROSPERO as CRD42022356301. A population, intervention, control, and outcomes (PICO) technique was utilized for report inclusion, and all reports were assessed for risk of bias by using the SYRCLE’s RoB tool. The article’s bibliographic information, induction model, type of proanthocyanidins, animal strain/weight/age, and outcome measurements were acquired from ten papers and are reported here. Further analysis was validated and determined for the review. The included studies met the review’s inclusion criteria and suggested that proanthocyanidins have a neurocognitive effect against AD. Additionally, the effectiveness of proanthocyanidins in reducing oxidative stress, acetylcholinesterase activity, amyloid beta, its efficacy in alleviating superoxide dismutase, cognitive properties, and in facilitating cholinergic transmission in various models of AD has been collectively observed in ten studies.

Figures

Similar articles

• Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

  Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.

• Anthocyanin as a therapeutic in Alzheimer’s disease: A systematic review of preclinical evidences.

  Suresh S, Begum RF, Singh S A, V C. Suresh S, et al. Ageing Res Rev. 2022 Apr;76:101595. doi: 10.1016/j.arr.2022.101595. Epub 2022 Feb 23. Ageing Res Rev. 2022. PMID: 35217244 Review.

• Potential neuroprotective benefits of plant-based fermented foods in Alzheimer’s disease: an update on preclinical evidence.

  Chen JH, Yin X, He H, Lu LW, Wang M, Liu B, Cheng KW. Chen JH, et al. Food Funct. 2024 Apr 22;15(8):3920-3938. doi: 10.1039/d3fo03805j. Food Funct. 2024. PMID: 38517682 Review.

• Galantamine for dementia due to Alzheimer’s disease and mild cognitive impairment.

  Lim AWY, Schneider L, Loy C. Lim AWY, et al. Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4. Cochrane Database Syst Rev. 2024. PMID: 39498781 Review.

• Grape Seed Proanthocyanidin Extract Ameliorates Streptozotocin-induced Cognitive and Synaptic Plasticity Deficits by Inhibiting Oxidative Stress and Preserving AKT and ERK Activities.

  Gao WL, Li XH, Dun XP, Jing XK, Yang K, Li YK. Gao WL, et al. Curr Med Sci. 2020 Jun;40(3):434-443. doi: 10.1007/s11596-020-2197-x. Epub 2020 Jul 17. Curr Med Sci. 2020. PMID: 32681248

References

Publication types

MeSH terms

Substances